Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

To investigate the efficacy of AMB-05X in patients with CRC with MRD as determined by a ctDNA(+) blood test and no clinically detectable radiographic disease.

Trial Details

NCT ID
NCT06617858
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • AMB-05X
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Histologic or pathologic confirmation of adenocarcinoma of the colon or rectum.
  • Completion of any curative intent therapies resulting in no evidence of disease (e.g., R0 resection) for stage I - IV CRC and has completed all pla…
  • No evidence of measurable radiographic disease according to RECIST 1.1 criteria (Eisenhauer et al. Eur. J Cancer 2009) and/or clinically detectable…
  • A positive ctDNA assay (Signatera) at least 28 days after completion of all planned standard of care treatment. Assays performed at external instit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →